Table 5.
Pathologic and adjuvant therapy outcomes for malignant neoplasia cases
| IA Group (RRCIA + LRCIA) N = 90 | EA Group (RRCEA + LRCEA) N = 81 | p value | |
|---|---|---|---|
| Tumor size (cm) | |||
| Mean ± SD [n] | 3.7 ± 2.3 [89] | 4.2 ± 2.5 [80] | 0.225 |
| TNM stage, N (%) | |||
| Stage 0 | 0 | 4 (4.9%) | 0.8004 |
| Stage I | 28 (31.5%) | 22 (27.2%) | |
| Stage II | 19 (12.2%) | 18 (14.5%) | |
| Stage III | 39 (43.8%) | 33 (40.7%) | |
| Stage IV | 3 (3.3%) | 4 (4.9%) | |
| Tumor Location, N (%) | |||
| Cecum | 47 (52.2%) | 34 (42.0%) | 0.1801 |
| Ascending colon | 30 (33.3%) | 38 (46.9%) | |
| Hepatic flexure | 10 (11.1%) | 5 (6.2%) | |
| Transverse colon | 2 (2.2%) | 4 (4.9%) | |
| Terminal Ileum | 1 (1.1%) | 0 | |
| Lymph node harvest | |||
| Mean ± SD [n] | 23.3 ± 10.0 [89] | 24.2 ± 9.5 [81] | 0.535 |
| Number lymph nodes positive | |||
| Mean ± SD [n] | 1.4 ± 2.7 [89] | 1.6 ± 5.5 [81] | 0.403 |
| Adjuvant chemotherapy, N (%) | 26 (29.2%) | 26 (32.9%) | 0.605 |
| Time to chemotherapy (days) | |||
| Mean ± SD [n] | 39.8 ± 14.5 [26] | 46.0 ± 20.2 [26] | 0.277 |
RRCIA robotic-assisted right colectomy intracorporeal anastomosis, LRCIA laparoscopic right colectomy intracorporeal anastomosis, RRCEA robotic-assisted right colectomy extracorporeal anastomosis, LRCEA laparoscopic right colectomy extracorporeal anastomosis